Skip to content

A study to assess the in use safety of a skin care product in healthy males and females

To evaluate the in use safety of a skin care formulations on healthy males and females - Nil

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/01/101843
Enrollment
99
Registered
2026-01-22
Start date
Unknown
Completion date
Unknown
Last updated
2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Dermacy Senicil Advanced Gentle Cleanser: Product will apply on whole face once in a day for the period of 14 days. Intervention2: Dermacy Senicil Advanced Intensive Moisturising Cream:

Sponsors

Lotus Herbals Pvt. Ltd.
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1)Indian Male and Female Asian Indian subjects 2)Healthy subjects 3)Skin is healthy on the studied anatomic unit 4)Having Sensitive skin type

Exclusion criteria

Exclusion criteria: 1 Being pregnant or breastfeeding or having stopped to breastfeed in the past three months 2 Having refused to give her assent by not signing the consent form 3 Taking part in another study liable to interfere with this study 4 Being insulin-dependent diabetic or non-insulin-dependent diabetic with a recent therapy (less than 6 months) 5 Having a progressive asthma (either under treatment or last fit in the last 2 years) 6 Having a chronic dermatosis liable to modify the cutaneous reactivity on the tested area (except for specific studies on a determined dermatosis) 7 Having non stabilized thyroid problems (requirement of a stabilized treatment for at least 6 months) 8 Being epileptic. 9 Following a chronic medicinal treatment comprising any of the following products: aspirin-based products, anti-inflammatories, antihistamines, corticotherapy, taken by general or local routes (the only medication permitted is paracetamol) 10 Having cutaneous hypersensitivity. 11 Having a diagnosed or highly probable allergy to one or several compounds of the cosmetic products. 12 Having undergone a surgery requiring a general anaesthetic of more than one hour in the past 6 months.

Design outcomes

Primary

MeasureTime frame
In use safetyTimepoint: Baseline, 30 minutes after product application, Day 1, Day 7, Day 14

Secondary

MeasureTime frame
NilTimepoint: NA

Countries

India

Contacts

Public ContactDr Mohit Lalvani

MASCOT-SPINCONTROL India Pvt. Ltd.

niharika@mascotspincontrol.in02243349191

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 7, 2026